"Novartis and Voyager Therapeutics Forge $1.2 Billion Neurologic Gene Therapy Alliance"
Novartis has expanded its gene therapy collaboration with Voyager Therapeutics, investing $100 million upfront to acquire capsids targeting Huntington’s disease and spinal muscular atrophy. The announcement, which comes ahead of the JP Morgan Healthcare Conference, has already positively impacted Voyager's stock, with shares increasing by 32%. Additionally, Novartis will purchase $20 million in Voyager shares, further cementing the partnership between the two companies in the field of neurologic gene therapies.
